23 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
to the personalized nature of autologous therapy, only one patient can be treated from each manufacturing run; the supply chain logistics, including manufacturing … and to also improve our supply chain capabilities. Figure 25 below describes the process we have developed for the manufacturing of CB-010 CAR-T cells. We use
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
clinical and commercial product development, manufacturing, and supply chain operations with large and small biopharmaceutical and cell and gene therapy
ARS
b7sftn6qac82ckmb
28 Apr 23
Annual report to shareholders
12:00am
DEF 14A
3k4otsywkozo0zvi2f
11 Aug 22
Definitive proxy
4:04pm
10-K
3hbwhfd
21 Mar 22
Annual report
4:19pm
8-K
EX-99.1
ywor0cnk65 5xqh
29 Sep 21
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng
4:15pm
10-Q
y3ge4zijvdex2
2 Sep 21
Quarterly report
4:28pm
424B4
p0pmcnto297s
23 Jul 21
Prospectus supplement with pricing info
4:24pm
S-1/A
p8f yyybu
19 Jul 21
IPO registration (amended)
6:09am